The Role of Insulin-Like Growth Factor 1 in the Progression of Age-Related Hearing Loss

Lourdes Rodríguez-de la Rosa 1,2,3, Luis Lassaletta 1,2,3,4, Miryam Calvino 3,4, Silvia Murillo-Cuesta 1,2,3*, and Isabel Varela-Nieto 1,2,3†

1 “Alberto Sols” Biomedical Research Institute CSIC-UAM, Madrid, Spain, 2 Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain, 3 Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 4 Otorhinolaryngology Department, Hospital La Paz, Madrid, Spain

Aging is associated with impairment of sensorial functions and with the onset of neurodegenerative diseases. As pari passu circulating insulin-like growth factor 1 (IGF-1) bioavailability progressively decreases, we see a direct correlation with sensory impairment and cognitive performance in older humans. Age-related sensory loss is typically caused by the irreversible death of highly differentiated neurons and sensory receptor cells. Among sensory deficits, age-related hearing loss (ARHL), also named presbycusis, affects one third of the population over 65 years of age and is a major factor in the progression of cognitive problems in the elderly. The genetic and molecular bases of ARHL are largely unknown and only a few genes related to susceptibility to oxidative stress, excitotoxicity, and cell death have been identified. IGF-1 is known to be a neuroprotective agent that maintains cellular metabolism, activates growth, proliferation and differentiation, and limits cell death. Inborn IGF-1 deficiency leads to profound sensorineural hearing loss both in humans and mice. IGF-1 haploinsufficiency has also been shown to correlate with ARHL. There is not much information available on the effect of IGF-1 deficiency on other human sensory systems, but experimental models show a long-term impact on the retina. A secondary action of IGF-1 is the control of oxidative stress and inflammation, thus helping to resolve damage situations, acute or made chronic by aging. Here we will review the primary actions of IGF-1 in the auditory system and the underlying molecular mechanisms.

Keywords: ARHL, GH, IGF system, presbycusis, rare diseases

IGF SYSTEM, UPSTREAM REGULATION, AND DOWNSTREAM IGF-1 SIGNALING

The mammalian IGF system is comprised of insulin-like growth factors (IGF), receptors and binding proteins (IGFBP). IGFs and insulin are small polypeptides produced as pre-pro-peptides that can bind the insulin (IR) and IGF-1 (IGF1R) tyrosine kinase receptors. IGFs also bind the cation-independent mannose-6-phosphatase IGF-2 receptor (IGF2R; Foulstone et al., 2005). The biological actions of IGFs are primarily mediated by binding to the IGF1R, a heterotetramer with extracellular IGF binding domains and intracellular tyrosine kinase domains. The carboxy-terminal domain has docking sites for intracellular substrates (IRSI-4/SHC; Laviola et al., 2007) that, in
turn, bind and activate a network of intracellular signaling molecules. Factor-receptor interactions are modulated by binding proteins (IGFBPs) and associated proteases. In plasma, IGFBPs carry IGFs and these regulate their half-life, distribution and biological actions. IGFBPs control the bioavailability of IGF-1 to its receptors by competing with receptors for free factors (Firth and Baxter, 2002).

The growth hormone (GH) is a peptide hormone secreted by somatotroph cells of the pituitary gland. GH stimulates the growth of all body tissues, thus its level rises progressively during childhood and peaks at puberty. IGF-1 is secreted by the liver as a result of stimulation by GH, which binds to its receptor, GHR, inducing homodimerization and initiating signal transduction through receptor-associated Janus kinase (JAK) 2 (Herrington et al., 2000). Activation of signal transducers and transcription activators of STAT5b family members is critical for regulating liver IGF-1 gene expression (Davey et al., 2001), as well as for the transcriptional regulation of other IGF system genes, including those coding for IGFBP3 and IGFALS. ALS is a secreted hepatic protein that can be found freely circulating or forming a ternary complex with IGF-1 and IGFBP-3, thus prolonging the half-life of IGF-1 and decreasing its availability to tissues (Boisclair et al., 2001).

At the cell surface, IGF-1 binds to high affinity IGF1R, inducing autophosphorylation and allowing docking of the receptor substrates IRS-1 to IRS-4, Grb2-associated binder 1 (Gab-1) and the Src homology 2 domain containing protein (SHC). Activated docking proteins subsequently recruit cytoplasmic components of downstream signaling pathways, including the MAPK (RAF-MEK-ERK1/2 and p38) and the PI3K-AKT pathways, and transduce the IGF signaling (Siddle, 2011). Depending on the cellular context, IGF-1 regulates different processes. For example, IGF-1 modulates gene expression in chondrocytes (Yang et al., 2017), protein synthesis in osteoblasts (Guo et al., 2017), cell cycle in enterocytes (Van Landeghem et al., 2015), metabolism in adipocytes (Chang et al., 2016), survival in cochlear hair cells (Yamahara et al., 2017) and autophagy in otic neural precursors (Aburto et al., 2012b). IGF1R can also translocate to the nucleus, activate transcription and regulate gene expression (Sehat et al., 2010).

Analysis of downstream signaling in the deaf Igf1−/− mouse has further contributed toward understanding its cochlear actions and demonstrated that an IGF-1 deficit is associated with activation of the p38 MAPK pathway (related to the cellular response to stress). RAF-ERK1/2 and AKT activity (cell proliferation and survival) are also impaired (Sanchez-Calderon et al., 2010) but the overall autophagic flux is unaffected (de Iriarte Rodriguez et al., 2015b; Magariños et al., 2017). Further analysis of IGF-1 signaling has been carried out by studying null mice for downstream targets such as IRS1 (Tang et al., 2017), IRS2, PTP1B (Murillo-Cuesta et al., 2012), GRF1 (Fernández-Medarde et al., 2009), and CRAF (De Iriarte Rodriguez et al., 2015a). Cochlear comparative transcriptomics have unveiled the role of FoxM1 and FoxP3 forkhead box transcription factors, and myocyte enhancer factor-2 (MEF-2) in inner ear development as well as IGF-1 cochlear actions (Sanchez-Calderon et al., 2010). The impact of IGF-1 deficiency depends on the tissue and organs studied. In the Igf1−/− mouse bone, cell survival and AKT signaling are gravely affected, but RAF kinase-mediated proliferation is not (Rodriguez-de La Rosa et al., 2014). In the mouse retina, however, IGF-1 deficit causes impairment of the autophagic flux, leading to increased inflammation, apoptosis and age-associated blindness (Rodriguez-de La Rosa et al., 2012; Arroba et al., 2016). Finally, analysis of the Igf1−/− vestibule has confirmed the role of p38 and added new players such as p53 and microRNAs (Rodriguez-de La Rosa et al., 2015).

In summary, IGF-1 has a role in brain development and maturation (Dyer et al., 2016). Later in life, bioactive IGF-1 circulating levels are reduced, a trend that has been associated with human frailty and cognitive decline (Vestergaard et al., 2014). IGF-1 deficiency leads to increased inflammation and to the failure of intracellular cell renewal mechanisms. This is critical in the inner ear because, as discussed below, none of the main cell types essential for hearing regenerate (Mittal et al., 2017).

INNER EAR DEVELOPMENT, ADULT ANATOMY, AND AGE-ASSOCIATED DEGENERATION

The inner ear develops from the otic ectodermal placode that invaginates to form the otic vesicle. This transitory embryonic structure contains the information required to generate most cell types of the adult inner ear, including the sensory cells and the auditory-vestibular neurons (Kelly and Chen, 2009; Magariños et al., 2012, 2014; Burns et al., 2015). Development of the inner ear is tightly regulated by intrinsic and extrinsic factors (Sanchez-Calderon et al., 2007; Gálvez et al., 2017). Among these factors, IGF-1 promotes proliferation and survival of otic progenitor cells, supports neurogenesis and facilitates late differentiation in species from fish to humans (Ayaso et al., 2002; Schlueter et al., 2007; Zou et al., 2009; Aburto et al., 2012a; Varela-Nieto et al., 2013; Tafra et al., 2014). IGF-1 plays a key role in brain development and maintenance of stem cells (Nieto-Estévez et al., 2016).

The adult inner ear comprises the cochlea and the vestibular organ, which are responsible for hearing and equilibrium, respectively. The organ of Corti in the cochlea contains highly specialized hair cells (inner -IHC- and outer -OHC-), which transform mechanical sounds into electrochemical signals that are conveyed to the brain by the VII vestibulocochlear cranial nerve (Stephenson, 2012). Sound induces the movement of hair cell stereocilia, causing the opening of ion channels, an influx of K+ ions and depolarization. Depolarization of IHC results in glutamate release and synapse with 10–30 afferent auditory bipolar neurons. Meanwhile, OHCs amplify the incoming sound stimulation and enhance frequency selectivity of the cochlear response (Fettiplace and Kim, 2014; Reichenbach and Hudspeth, 2014). The organ of Corti is connected to the brain by two types of neurons in the spiral ganglion (SGN; Coate and Kelley, 2013). Type I and type II neurons innervate IHC and OHC respectively. Of these two kinds of neurons, type I is the most abundant (95%). The SGN
| (Woods et al., 1996) | (Batey et al., 2014) | (Walenkamp et al., 2009) | (Netchine et al., 2009) | (Shaheen et al., 2014) | (Fuqua et al., 2012) | (Van Duyvenvoorde et al., 2010, 2011) |
| --- | --- | --- | --- | --- | --- | --- |
| Mutation type | Homozygous Deletion | Heterozygous Deletion | Homozygous Missense mutation | Homozygous Missense mutation | Homozygous Missense mutation | Heterozygous Splicing mutation |
| Mutational analysis | 181-bp deletion of IGF1 gene (ex 4–5) | 262-kb deletion of chr 12 (IGF1 gene) | Val44Met c.274G?A, p.V44M | Arg36Gln c.251G?A, p.R36Q (ex 4) | ArgGly105 c.292C?T, p.R98W | Stop codon excision ex 4 c.402+1G, p.744Rfs*8 |
| Clinical data | ♂ 15.8 yr Intrauterine growth restriction Postnatal growth failure Microcephaly Clinodactyly Mild myopia Cognitive delay | ♂ 2.3–8.4 yr Intrauterine growth restriction Postnatal growth failure Microcephaly Clinodactyly Severe cognitive delay Deaf-mutism | ♂ 55 yr Intrauterine growth restriction Postnatal growth failure Microcephaly Clinodactyly Mild myopia Cognitive delay | ♂ 11 mo–9 yr Intrauterine growth restriction Progressive postnatal growth failure Microcephaly Non-dysmorphic features Mild cognitive delay | ♂ 2.8 yr (sibling-1) | ♂ 5 yr (sibling-2) |
| | ♂ 11 mo–9 yr Intrauterine growth restriction Progressive postnatal growth failure Microcephaly Clinodactyly Mild cognitive delay | ♂ 55 yr Intrauterine growth restriction Postnatal growth failure Microcephaly Clinodactyly Mild myopia Cognitive delay | ♂ 11 mo–9 yr Intrauterine growth restriction Progressive postnatal growth failure Microcephaly Clinodactyly Mild cognitive delay | ♂ 2.8 yr (sibling-1) | ♂ 5 yr (sibling-2) |
| | | | | ♂ 55 yr Intrauterine growth restriction Postnatal growth failure Microcephaly Clinodactyly Mild cognitive delay | ♂ 2.8 yr (sibling-1) | ♂ 5 yr (sibling-2) |
| Consanguinity | Yes | No | Yes | Yes | Yes | No |
| Birth weight (kg) | 1.4 (−3.9SD) | 2.7 (−1.5SDS) | 1.4 (−3.9SDS) | 2.3 (−2.4SDS) | Sib-1: 1.6 (−3.5SDS) | Sib-2: ND |
| Birth length (cm) | 37.8 (−5.4SD) | 47.6 (−1.2SDS) | 39 (−4.3SDS) | 44 (−3.7SDS) | ND | 47 (−0.6SDS) |
| Growth weight (kg) | 15.8 yr: 23 (−6.5SD) | 2.3 yr: 8.8 (−3.8SDS) | 5.3 yr: 14.4 (−2.5SDS) | 8.4 yr: 21.9 (−1.6SDS) | ND | 11 mo: 5.5 (−5.0SDS) | 2.8 yr: 7.0 (−7.0SDS) |
| Growth height (cm) | 15.8 yr: 119.1 (−6.9SD) | 2.3 yr: 77.5 (−3.1SDS) | 5.3 yr: 96.9 (−2.9SDS) | 8.4 yr: 114.9 (−2.7SDS) | ND | 11 mo: 64 (−3.7SDS) | 2.8 yr: 76 (−4.9SDS) |
| Hearing impairment | 15.8 yr: severe bilateral HL | Normal hearing | 55 yr: severe bilateral HL | 9 yr: normal hearing | ND | ND |
| IGF-1 levels (ng/mL) | Undetectable | Low-normal | Very high | Low | ND | Low-normal |
| | 15 yr: ?3 | 2.3 yr: 43.7; 5.3 yr: 58.5 | 55 yr: 606 (+7.3SDS) | 2.7 yr: 11 (before GH treatment) | ND | 9.3 yr: 115 (−2.2SDS) |
| | | 8.4 yr: 100 | 55 yr: 606 (+7.3SDS) | | | (before GH treatment) |
| | | | | 2.7 yr: 11 (before GH treatment) | ND | | |
| | IGFBP-3 levels (mg/L) | Normal | Normal | Normal | Normal | Normal |
| | 15 yr: 3.3 | 5.3 yr: 4.3 | 8.4 yr: 5.4 | 55 yr: 1.98 (+0.1SDS) | Normal | Normal |
| | | | | (after GH treatment) | 9.3 yr: 8.2 | (before GH treatment) |
| | | | | | 8.2 yr, sib-1: 3.6 (1.2SDS) | Normal |
| | | | | | 6.2 yr, sib-2: 2.1 (0.1SDS) | |

(Continued)
| ALS levels (mg/L) | IGFR-1 affinity for IGFR | % | ND | No affinity | Normal to high (after GH treatment) | Extremely low | Partially reduced | 3.9-fold lower | Extremely low | 90-fold lower | ND | ND | No affinity |
|-------------------|-------------------------|---|----|------------|-----------------------------------|--------------|------------------|---------------|--------------|--------------|-----|-----|------------|
| (Woods et al., 1996) | | | | | | | | | | | | | | |
| (Batey et al., 2014) | | | | | | | | | | | | | | |
| (Walenkamp et al., 2005) | | | | | | | | | | | | | | |
| (Netchine et al., 2009) | | | | | | | | | | | | | | |
| (Shaheen et al., 2014) | | | | | | | | | | | | | | |
| (Fuqua et al., 2012) | | | | | | | | | | | | | | |
| (Van Duyvenvoorde et al., 2010, 2011) | | | | | | | | | | | | | | |

**axons form the cochlear branch of the vestibulocochlear nerve and connect the peripheral spiral ganglia with the cochlear nuclei at the brainstem.** Sound information progresses in a complex multisynaptic, parallel, and ascendant pathway from the cochlea through the brainstem nuclei to the auditory cortex, preserving the tonotopic organization (Tsukano et al., 2017).

Expression levels of IGF-1 and its high affinity receptor, IGFR1, are elevated during late cochlear development, decline significantly after birth, but baseline expression is maintained throughout the organism's life (Murillo-Cuesta et al., 2011; Okano et al., 2011). In the mouse cochlea, IGF-1 is clearly detected in spiral ganglion neurons and stria vascularis, and its expression is modulated with aging (Riva et al., 2007). IGF binding proteins are also expressed in the developing ear and throughout life (Okano and Kelley, 2013). Finally, IGF system elements are expressed in the vestibular system over a similar time course (Degerman et al., 2013; Rodríguez-de la Rosa et al., 2015).

During aging, peripheral and central auditory structures degenerate, leading to ARHL (Fetoni et al., 2011). The primary pathological alterations observed in mouse models include progressive degeneration and loss of HC and SGN (Bao and Ohlemiller, 2010; Bowl and Dawson, 2015), as well as changes in the central auditory pathway. Typically, presbycusis debuts with loss of OHC, mainly in basal cochlear regions (high frequencies), and extends toward the apex and IHC (Ohlemiller and Gagnon, 2004). OHC defects result in a moderate increase of the hearing threshold, whereas defects in IHC or the auditory neurons can lead to profound deafness (Ouda et al., 2015). Swelling of the afferent nerve terminals and a decrease in the density of their associated ribbon synapses causes a synaptopathy that is sometimes the primary defect (Wan and Corfas, 2015).

The stria vascularis is a three-cell layer structure within the cochlea that maintains the K⁺ concentration and the endocochlear potential (Magariños et al., 2012). During aging, the stria vascularis shows disorganization and atrophy, with loss of marginal cells and progressive merging of strial capillaries (Ohlemiller, 2009). In addition, thinning, degeneration of fibrocytes and loss of capillaries are observed in the spiral ligament (Hequembourg and Liberman, 2001). In human cohorts, decreased age-related-IGF-1 bioavailability correlates with progression of hearing impairment (Lassale et al., 2017), as will be discussed in depth below. Studies carried out with Igf1−/− and Igf1−/+ mice confirmed this trend and showed acceleration in the damage of the neural structures and stria vascularis (Riquelme et al., 2010).

The molecular mechanisms underlying ARHL that have been described include redox imbalance, accumulation of mitochondrial DNA damage, and excitotoxicity, leading to apoptotic and necrotic cell death (Menardo et al., 2012; Wong and Ryan, 2015). Interestingly, experimental models indicate that anti-oxidant therapy and control of micronutrients could prevent or ameliorate ARHL (Fetoni et al., 2009; Guastini et al., 2011; Ding et al., 2016). These mechanisms are similar to those involved in drug- and noise-induced hearing loss (Frisina et al., 2016; Kalinec et al., 2017).
| Gene | HGDM<sup>®</sup> mutations (number) | General phenotype | Deafness mutation | Clinical cases | Auditory phenotype | References |
|------|----------------------------------|-------------------|-------------------|---------------|-------------------|------------|
| GHRHR | Missense (26) | Severe dwarfism | Homozygous splice mutation (c.5711G>A) | 26 (13♂, 13♀) | ↑ prevalence of dizziness Early mild high-tone SNHL | Prado-Barreto et al., 2014 |
| | Splicing (10) | Central obesity | | 47.6 ± 15.1 yr | ↓ Systolic blood pressure | |
| | Regulatory (4) | ↑ LDL cholesterol levels | | | ↓ Transient evoked otocoustic emissions | |
| | Small del (4) | ↑ Systolic blood pressure | | | | |
| | Small ins (2) | Granular volume, frontal bossing | | | | |
| | Gross del (1) | Depth of skull, facial height, Laryngopharyngeal reflex | Laryngeal constriction | ↓↓ GH and IGF-1 serum levels | |
| GHR | Missense (56) | Laron syndrome | GH-R-W-15X (exon 2) | 5 untreated (2♂, 3♀), 49.2 ± 4.8 yr | Hearing impairment (50% low-tone SNHL; 16.6% high-tone SNHL; 25% combined high-low-tone SNHL; 8.3% mixed HL) | Attias et al., 2012 |
| | Splicing (21) | Dwarfism | GH-R-R217X (exon 7) | 1 with delayed rhIGF-1 treatment (♂, 15 yr) | | |
| | Small del (4) | Obesity | GH-R-3,5,6 exon del | | | |
| | Small ins (4) | Hypogonadism | GH-R-43X/Norm (exon 4) | | | |
| | Gross del (9) | Hypoglycemia at birth and in early infancy | | | | |
| | Complex (1) | | | | | |
| PTPN11 | Missense (111) | Noonan syndrome (craniofacial dysmorphic features, short stature, congenital heart defects, including pulmonary stenosis; Electrocardiogram conduction abnormalities; ocular hypertelorism; cleft lip/palate; ambiguous genitalia; retardation of growth) | Heterozygous missense mutation (c.1381G>A) | 5 yr ♀ | Bilateral profound SNHL Enlarged vestibular aqueducts | Chu et al., 2013 |
| | Splicing (4) | | | | | |
| | Small del (7) | | | | | |
| | Small ins (1) | Leopard syndrome lentigines; Electrocardiogram conduction abnormalities; ocular hypertelorism; cleft lip/palate; ambiguous genitalia; retardation of growth | | | | |
| | Small indels (3) | | | | | |
| | Gross del (1) | | | | | |
| | Gross ins (3) | | | | | |
| | Complex (1) | | | | | |
| | Repeats (2) | | | | | |
| | SNHL (15-25% of patients with Leopard syndrome) | | | | | |
| | Missense mutation (c.836A>G, Tyr279Qys) | 17 yr ♀ | Severe bilateral SNHL | | Martinez-Quintana and Rodríguez-González, 2012 |
| | Missense mutation in exon 7 (836A>G, Tyr279Qys) | 16 yr ♀ | Severe bilateral SNHL | | Kim et al., 2011 |
| | Mutation c.1510A>G | Neonatal ♀ | Severe congenital HL | | Van Nieop et al., 2017 |
| | Mutation c.124A>G | Neonatal ♀ | Severe congenital HL | | |
| | Mutation c.922A>G | Neonatal ♀ | Severe congenital HL and multiple ear infections. | | |
| | Mutation c.124A>G | 1 yr ♀ | Progressive SNHL, otitis media | | |
| | Mutation c.836A>G | Neonatal ♀ | Severe congenital HL | | |
| | c.124A>G c.179G>C, c.181G>A, c.182A>G | Both sexes | Temporary hearing impairment (sensorineural, Conductive, mixed) | | van Trier et al., 2015 |
| | c.186A>G, c.236A>G | | Variable age | | |
| | c.417G>c.794G>A, c.922A>G, c.923A>G | | External ear anomalies (81%) | | |
TABLE 2 | Continued

| Gene | HGDM® mutations (number) | General phenotype | Clinical cases | Deafness mutation | Auditory phenotype |
|------|--------------------------|-------------------|---------------|-------------------|-------------------|
| IGF1R | Missense (36), Splicing (1), Regulatory (1), Small del (1), Small ins (4), Gross del (12), Gross ins (5), Complex (2) | Moderate-severe growth failure, Mild intellectual impairment, Microcephaly, Dysmorphic features, Cardiac malformations, Disturbed glucose tolerance, Failure to thrive | Two siblings, 11 yr and 7 yr♂ | Deafness | Deafness |
|       | Deletion p.A711_E714del | Bilateral HL, Recurrent ear infections | 3 yr♀ | Partial deletion (exons 3–21) | Bilateral HL |

| References | | | | | |
| Mayshado et al., 2015 | Ester et al., 2009 | | | |

The central auditory system shows alterations that could be secondary to the diminished input from the damaged periphery. These include modifications in the expression of calcium binding proteins (parvalbumin, calbindin and calretinin, and glutamate-decarboxylase), atrophy of the gray and white matter and changes in the content of some metabolites (Ouda et al., 2015). However, a minimal age-related decline in the total number of neurons in central auditory structures has been reported. IGF-1 expression is modulated by cochlear damage in the auditory central pathway (Alvarado et al., 2007) and its deficit also impacts neurotransmission in the cochlear nucleus (Fuentes-Santamaria et al., 2013, 2016).

To summarize, IGF system elements are expressed in the inner ear and central auditory pathway, and their expression is regulated by damage and age in different species. The importance of this system in hearing loss has been further proven by the study of human mutations and human cohorts as described below.

ASSOCIATION OF THE IGF SYSTEM WITH HUMAN GENETIC DEAFNESS AND AGE-RELATED HEARING LOSS

ARHL is a multifactorial process that results in cochlear damage over the span of a life. Noise, otoxic agents, trauma, vascular insults, metabolic changes, hormones, diet, immune system, and genetic predisposition are all contributing factors (Gates and Mills, 2005; Fetoni et al., 2011). Given the increase in the average age of the population as well as in noxious environmental agents, the impact of ARHL is continuously growing.

The relationship between nutrition and ARHL is an emerging interdisciplinary field and recent evidence points to vitamin imbalances and high fat diets as risk factors (Partearroyo et al., 2017). In addition, the genetic study of ARHL is an expanding field that has rendered several gene candidates thus far (Salminen and Kaarniranta, 2010; Op De Beeck et al., 2011; Fransen et al., 2015; Koffler et al., 2015).

Mutations in human genes coding for IGF-1, IGF1R, and other members of the GH/IGF-1 system cause rare diseases (Tables 1, 2), which normally have an early onset. Patients show growth retardation and frequent microcephaly. Interestingly, only when IGF-1 actions are totally impaired do the affected patients show syndromic hearing loss (Table 1). Indeed, of the 7 mutations described in young humans, hearing phenotype of 2 patients have not been reported (Van Duyvenvoorde et al., 2010, 2011; Shaheen et al., 2014) and 3 show low to normal IGF-1 levels, which show reduced affinity for IGF1R binding in the case tested, and normal hearing (Netchine et al., 2009; Fuqua et al., 2012; Batey et al., 2014). No data have been published on the evolution of hearing loss associated with aging that these patients present. Finally, 2 patients showed severe hearing loss which was associated in one case with total absence of circulating IGF-1 (Woods et al., 1996) and in the other with an extremely low binding affinity (Walenkamp et al., 2005). Accordingly, haploinsufficient IGF-1 availability causes growth retardation and has been associated with short adult stature and hearing loss in other genetic syndromes such as Noonan’s or Turner’
Human mutations in the gene coding for the high affinity receptor IGFR1 are even less frequent and normally found in heterozygosis (Table 2; Abuzzahab et al., 2003; Ester et al., 2009; Klammt et al., 2011; Fang et al., 2012; Gannagé-Yared et al., 2013; Prontera et al., 2015). Reduced bioactive IGF-1 levels caused by mutations in related genes, such as those coding for GH and the GHR, are also associated with hearing loss (Table 1; Giordano et al., 2015; Muus et al., 2017). In general, the authors have not done a thorough study of sensory functions, including hearing. However, it is worth noting that Laron’s syndrome patients have been studied in depth and show early onset of ARHL (Attias et al., 2012). Laron’s syndrome is an autosomal recessive human disorder characterized by mutations in the GHR that cause insensitivity to GH stimuli and, in turn, extremely low IGF-1 synthesis in the liver. Patients have a short stature, among other characteristics, and normal hearing at young ages but develop early onset ARHL, which could be prevented by IGF-1 treatment. Still, much work is needed to fully understand the relationship between genes associated with short stature (Baron et al., 2015; Wit et al., 2016) and hearing loss.

Finally, epidemiologic studies of aging cohorts have shown a relationship between bioactive IGF-1 and hearing loss (Lassale et al., 2017). Furthermore, there is increasing evidence linking these two factors with cognitive decline and onset of neurodegenerative diseases (Dik et al., 2003; Watanabe et al., 2005; Fortunato et al., 2016; Lassale et al., 2017; Wrigley et al., 2017), dementia (Percacio, 2014; Su et al., 2017), depression (Van Varsseveld et al., 2015; Kim et al., 2017), short stature (Barrenás et al., 2005a; Crowe et al., 2011), cardiovascular pathologies (Burgers et al., 2011; Tan et al., 2017), and aging (Bainbridge and Wallhagen, 2014; Vestergaard et al., 2014).

These data lead us to pose the following questions: (i) which cochlear processes are IGF-1-dependent and dramatically impaired during aging? And (ii) is there a potential for prevention and repair interventions based on IGF-1 targets? Insight into the first question has been obtained from the study of the Igf1<sup>−/−</sup> mouse that shows profound syndromic bilateral sensorineural hearing loss (Cediel et al., 2006). The main cellular alterations reported were delayed postnatal development, a significant decrease in the number and size of auditory neurons, aberrant innervation patterns, increased neural apoptosis, deficits in myelination and increased efficacy of glutamatergic synapses (Camarero et al., 2001, 2002; Sanchez-Calderon et al., 2007; Fuentes-Santamaría et al., 2016). Igf1<sup>−/−</sup> mice develop further cellular degeneration with aging. As bioactive IGF-1 levels decrease, the heterozygous mice also show an accelerated hearing loss secondary to degeneration of the SGN (Riquelme et al., 2010). Our findings support the idea that IGF-1 levels may hold predictive value for the stratification of ARHL and, secondary to hearing loss, for cognitive decline. Regarding the aforementioned mechanisms, IGF-1 is a neurotrophic factor with anti-inflammatory actions. It is anti-apoptotic and favors cell renewal.

In this context, IGF-1 emerges as a potential protector of the inner ear. Studies in animal models have shown that local application of recombinant human IGF-1 (rhIGF-1) protects the cochlea from functional and histologic losses induced by aminoglycoside ototoxicity and noise exposure (Iwai et al., 2006; Yamahara et al., 2015). IGF-1 rescued hair cells from apoptosis by downregulating pro-apoptotic gene expression and regulating glucose transporters (Yamahara et al., 2015). Similarly, IGF-1 and substance P protect vestibular hair cells against neomycin ototoxicity (Yoshida et al., 2015). Recombinant IGF-1 therapy has been approved to increase linear growth, and therefore height, in humans, spurring an increasing interest in the potential use of IGF-1 for the treatment of hearing loss (Yamahara et al., 2015). IGF-1 potential has been studied in patients with sudden sensorineural hearing loss who were resistant to treatment with systemic glucocorticoids (Nakagawa et al., 2012, 2014). A recent study with 120 patients concluded that treatment with topical IGF-1 therapy had significant effects on hearing recovery depending on their age (<60 years) and early initiation of salvage treatment (Nakagawa et al., 2016). Prolonged activation of IGFR1 by treatment with IGF-1 or analogs might have undesired secondary effects, thus their potential use to delay aging maybe limited. However available data highlight the interest of exploring IGF-1 downstream targets as drug candidates for ARHL.

**AUTHOR CONTRIBUTIONS**

LR-dlR, LL, MC, SM-C, IV-N: drafted the work and wrote the manuscript; LR-dlR, SM-C, and IV-N: revised the manuscript. All authors approved the manuscript in its final form.

**FUNDING**

This work was supported by the European Commission FP7-PEOPLE-2013-IAPP TARGET, Spanish MINECO/European Social Funds (FEDER) SAF2014-53979-R and CIBERER-ISCiii MODCELANI_Crispr ER165PAC761, and FENOCRISPR ER17P5AC7612 to IV-N. LR-dlR and SM-C are supported by FEDER/CIBERER contracts.

**ACKNOWLEDGMENTS**

We warmly thank our present and former colleagues in the Neurobiology of Hearing group for sharing information and for useful discussions.

**REFERENCES**

Aburto, M. R., Sánchez-Calderón, H., Hurlé, J. M., Varela-Nieto, I., and Magariños, M. (2012b). Early otic development depends on autophagy for apototic cell clearance and neural differentiation. *Cell Death Dis.* 3:e394. doi: 10.1038/cddis.2012.132

Abuzzahab, M. J., Schneider, A., Goddard, A., Grigorescu, F., Lautier, C., Keller, E., et al. (2003). IGF-I receptor mutations resulting in intrauterine
Fortunato, S., Forlì, F., Guglielmi, V., De Corso, E., Paludetti, G., Berretti, S., et al. (2016). A review of new insights on the association between hearing loss and cognitive decline in ageing. Acta Otorhinolaryngol. Ital. 36, 155–166. doi:10.14639/0392-100X-993

Foulstone, E., Prince, S., Zaccheo, O., Burns, J. L., Harper, J., Jacobs, C., et al. (2005). Insulin-like growth factor-1 ligands, receptors, and binding proteins in cancer. J. Pathol. 205, 145–153. doi:10.1002/path.1712

Fransen, E., Bonneux, S., Combeaux, J. J., Schauren, I., Di Berardino, F., White, C. H., et al. (2015). Genome-wide association analysis demonstrates the highly polygenic character of age-related hearing impairment. Eur. J. Hum. Genet. 23, 110–115. doi:10.1038/ejhg.2014.56

Frisina, R. D., Ding, B., Zhu, X., and Walton, J. P. (2016). Age-related hearing loss: prevention of threshold declines, cell loss and apoptosis in spiral ganglion neurons. Aging 8, 2081–2099. doi:10.18632/aging.101045

Fuentes-Santamaria, V., Alvarado, J. C., Gabaldon-Ull, M. C., and Manuel Juiz, J. (2017). Upregulation of insulin-like growth factor and interleukin 1β occurs in neurons but not in glial cells in the cochlear nucleus following cochlear ablation. J. Comp. Neurol. 521, 3478–3499. doi:10.1002/cne.23362

Fuentes-Santamaria, V., Alvarado, J. C., Rodríguez-De La Rosa, L., Murillo-Cuesta, S., Contreas, J., Juiz, J. M., et al. (2016). IGFl deficiency causes atrophic changes associated with upregulation of VGlut1 and downregulation of MEF2 transcription factors in the mouse cochlear nucleus. Brain Struct. Funct. 221, 709–734. doi:10.1007/s00429-014-0934-2

Fuqua, J. S., Derr, M., Rosenfeld, R. G., and Hwa, V. (2012). Identification of a novel heterozygous IGF1 splicing mutation in a large kindred with familial short stature. Horm. Res. Paediatr. 78, 59–66. doi:10.1159/000337249

Gálvez, H., Abelló, G., and Giraldez, F. (2017). Signaling and transcription factors during inner ear development: the generation of hair cells and otic neurons. Front. Cell Dev. Biol. 5:21. doi:10.3389/fcell.2017.00021

Gannagé-Yared, M. H., Klammt, J., Chouery, E., Corbani, S., Mégarbäné, H., Gálvez, H., Abelló, G., and Giraldez, F. (2017). Signaling and transcription factors in LEOPARD syndrome with PTPN11 gene mutation showing six cardinal malformations, deafness and insulin insensitivity, in Endocrine Society’s 97th Annual Meeting and Expo (San Diego).

Hequembourg, S., and Liberman, M. C. (2001). Spiral ligament pathology: a major cause of SGA. Acta Otorhinolaryngol. Ital. 21, 466–470. doi:10.1016/j.otc.2015.07.007

Kim, S. Y., Kim, H. J., Park, E. K., Joe, J., Sim, S., and Choi, H. G. (2017). Severe hearing impairment and risk of depression: a national cohort study. PLoS ONE 12:e0179793. doi:10.1371/journal.pone.0179793

Klammt, J., Kiess, W., and Pfäffle, R. (2011). IGFIR mutations as cause of SGA. Best Pract. Res. Clin. Endocrinol. Metab. 25, 191–206. doi:10.1016/j.beem.2010.09.012

Koeller, T., Ushakov, K., and Avraham, K. B. (2015). Genetics of hearing loss: syndromic. Otolaryngol. Clin. North Am. 48, 1041–1061. doi:10.1016/j.otc.2015.07.007

Lassale, C., Batty, G. D., Steptoe, A., and Zaninotto, P. (2017). Insulin-like Growth Factor 1 in relation to future hearing impairment: findings from the English Longitudinal Study of Ageing. Sci. Rep. 7, 4212. doi:10.1038/s41598-017-00556

Laviola, L., Natalichio, A., and Giorgino, F. (2007). The IGF-I signaling pathway. Curr. Pharm. Des. 13, 663–669. doi:10.2174/138182707780249146

Magariños, M., Contrezas, J., Aburto, M. R., and Varela-Nieto, I. (2012). Early development of the vertebrate inner ear. Anat. Rec. 295, 1775–1790. doi:10.1002/ar.22575

Maysted, I., Andrew, S. F., De Schepper, J., Wauters, N., Benoît, V., Joset, P., et al. (2015). “Novel Homozygous IGF1 Receptor (IGFIR) mutation, p.A711_E714del, in two siblings with severe growth failure, congenital malformations, deafness and insulin insensitivity,” in Endocrine Society’s 97th Annual Meeting and Expo (San Diego).

Menardo, J., Tang, Y., Ladrech, S., Lenoir, M., Casas, F., Michel, C., et al. (2012). Oxidative stress, inflammation, and autophagic stress as the key mechanisms of premature age-related hearing loss in SAMP8 mouse Cochlea. Antioxid. Redox Signal. 16, 251–274. doi:10.1159/2013.10437

Nagayo, N., Sato, T., Park, K. Y., Park, J., Tsuyama, T., Kaneko, Y., et al. (2013). Water-soluble coenzyme Q10 formulation in presbycusis: long-term effects. Auris Nasus Larynx 40, 189–195. doi:10.1016/j.anl.2015.12.004

Nieto, I. (2017). The role of insulin-like growth factor-I in the physiopathology of hearing. Front. Mol. Neurosci. 10:411. doi:10.3389/fnmol.2017.00411

Nieto, I. (2011). The role of insulin-like growth factor-1 in the physiopathology of hearing. Front. Mol. Neurosci. 4:11. doi:10.3389/fnmol.2011.00011

Muus, J. S., Weir, F. W., Kreicher, K. L., Bowly, D. A., Discolo, C. M., and Meyer, T. A. (2017). Hearing loss in children with growth hormone deficiency. Int. J. Pediatr. Otorhinolaryngol. 100, 107–113. doi:10.1016/j.ijpolor.2017.06.037

Nakagawa, T., Kumakawa, K., Usami, S., Hato, N., Tabuchi, K., Takahashi, M., et al. (2014). A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment. BMC Med. 12:219. doi:10.1186/s12916-014-0219-x

Nakagawa, T., Oginoh-Nishimura, H., Hiraumi, H., Sakamoto, T., Yamamoto, N., and Ito, J. (2012). Audiometric outcomes of topical IGF1 treatment for sudden deafness refractory to systemic steroids. Otol. Neurotol. 33, 941–946. doi:10.1097/MAO.0b013e31825f251a

Nakagawa, T., Yamamoto, M., Kumakawa, K., Usami, S., Hato, N., Tabuchi, K., et al. (2016). Prognostic impact of salvage treatment on hearing recovery in patients with sudden sensorineural hearing loss refractory to systemic corticosteroids: a retrospective observational study. Auris Nasus Larynx 43, 489–494. doi:10.1016/j.anl.2015.12.004

Netchine, I., Azzi, S., Houang, M., Seurin, D., Ricort, J. M., et al. (2009). Partial primary deficiency of insulin-like growth factor (IGF-1) activity associated with IGF1 mutation demonstrates its critical role in growth and brain development. J. Clin. Endocrinol. Metab. 94, 3913–3921. doi:10.1210/jc.2009-0452
Nieto-Estévez, V., Ouelslati-Morales, C. O., Li, L., Pickel, J., Morales, A. V., and Vicario-Abéjón, C. (2016). Brain insulin-like growth factor-i directs the transition from stem cells to mature neurons during postnatal/adult hippocampal neurogenesis. Stem Cell 34, 2194–2209. doi: 10.1002/stem.1397

Ohlemiller, K. K. (2009). Mechanisms and genes in human strial presbycusis from animal models. Brain Res. 1277, 70–83. doi: 10.1016/j.brainsres.2009.02.079

Ohlemiller, K. K., and Gagnon, P. M. (2004). Cellular correlates of progressive hearing loss in 12956/EvSn mice. J. Comp. Neurol. 469, 377–390. doi: 10.1002/cne.11011

Okano, T., and Kelley, M. W. (2013). Expression of insulin-like growth factor binding proteins during mouse cochlear development. Dev. Dyn. 242, 1210–1221. doi: 10.1002/dvdy.24005

Okano, T., Xuan, S., and Kelley, M. W. (2011). Insulin-like growth factor signaling regulates the timing of sensory cell differentiation in the mouse cochlea. J. Neurosci. 31, 18104–18118. doi: 10.1523/JNEUROSCI.3619-11.2011

Op De Beeck, K., Schacht, J., and Van Camp, G. (2011). Apoptosis in acquired and genetic hearing impairment: the programmed death of the hair cell. Hear. Res. 281, 18–27. doi: 10.1016/j.heares.2011.07.002

Ouda, L., Profant, O., and Syka, J. (2015). Age-related changes in the central auditory system. Cell Tissue Res. 361, 337–358. doi: 10.1007/s00441-014-1917-9

Partearroyo, T., Vallecillo, N., Pajares, M. A., Varela-Moreiras, G., and Varela-Nieto, I. (2017). Cochlear homocysteine metabolism at the crossroad of nutrition and senescent hearing loss. Front. Mol. Neurosci. 10:177. doi: 10.3389/fnmol.2017.01017

Peracino, A. (2014). Hearing loss and dementia in the aging population. Audiol. Neurootol. 19(Suppl. 1), 6–9. doi: 10.1155/2013/517959

Prado-Barreto, V. M., Salvadori, R., Santos Júnior, R. C., Brandão-Martins, M. B., Correa, E. A., Garcez, F. B., et al. (2014). Hearing status in adult individuals with lifetime, untreated isolated growth hormone deficiency. Otolaryngol. Head Neck Surg. 150, 464–471. doi: 10.1177/0194599813517987

Proriera, P., Micale, L., Verrotti, A., Napoleon, V., Stangoni, G., and Merla, G. (2015). A new homozygous IGF1R variant defines a clinically recognize incomplete dominant form of SHORT syndrome. Hum. Mutat. 36, 1043–1047. doi: 10.1002/humu.22853

Reichenbach, T., and Hudspeth, A. J. (2014). The physics of hearing: fluid mechanics and the active process of the inner ear. Rep. Prog. Phys. 77:076601. doi: 10.1088/0034-4885/77/7/076601

Riquelme, R., Cederi, R., Contreras, I., La Rosa Lourdes, R. D., Murillo-Cuesta, S., Hernandez-Sanchez, C., et al. (2010). A comparative study of age-related hearing loss in wild type and insulin-like growth factor 1 deficient mice. Front. Neuroanat. 4:27. doi: 10.3389/fnana.2010.00027

Riva, C., Donadié, E., Magnan, J., and Lavieille, J. P. (2007). Age-related hearing loss in CD/1 mice is associated to ROS formation and HIF target genes up-regulation in the cochlea. Exp. Gerontol. 42, 327–336. doi: 10.1016/j.exger.2006.10.014

Rodriguez-de la Rosa, L., Fernandez-Sanchez, L., Germain, F., Murillo-Cuesta, S., Varela-Nieto, I., de la Villa, P., et al. (2012). Age-related functional and structural retinal modifications in the Igf1-/- null mouse. Neuroanat. Neurootol. 24, 695–703. doi: 10.1016/j.ijporl.2017.04.024

Tsukano, H., Horie, M., Ohga, S., Takahashi, K., Kubota, Y., Hishida, R., et al. (2017). Reconsidering tonotopic maps in the auditory cortex and lemniscal auditory thalamus in mice. Front. Neural Circuits 11:14. doi: 10.3389/fncir.2017.00014

Tan, H. E., Lam, N. S. R., Knuiman, M. W., Divitini, M. L., Swanepoel, D. W., Hunter, M., et al. (2017). Associations between cardiovascular disease and its risk factors with hearing loss-A cross-sectional analysis. Clin. Otolaryngol. doi: 10.1111/coa.12936

Tang, C. Y., Man, X. F., Guo, Y., Tang, H. N., Tang, J., Zhou, C. L., et al. (2017). IRS-2 partially compensates for the insulin signal defects in IRS-1-/- mice mediated by miR-33. Mol. Cells 40, 123–132. doi: 10.1007/s10059-017-0122-x

Varela-Nieto, I., Murillo-Cuesta, S., Rodriguez-de la Rosa, L., Lasatetta, L., and Vicario-Abejon, C. (2016). Brain insulin-like growth factor-1 target genes: implication of MEF2 and FOXM1 transcription factors. PLoS ONE 8:e8699. doi: 10.1371/journal.pone.008699

Varela-Nieto, I., Murillo-Cuesta, S., Lasatetta, L., and Contreras, J. (2013). IGF-1 deficiency and hearing loss: molecular clues and clinical implications. Pediatr. Endocrinol. Rev. 10, 460–472

Verales-Nieto, I., Murillo-Cuesta, S., Rodriguez-de la Rosa, L., Lassalletta, L., and Contreras, J. (2015). IGF-1 deficiency and hearing loss: molecular clues and clinical implications. Pediatr. Endocrinol. Rev. 10, 460–472

Vestergaard, P. F., Hansen, M., Frystyk, J., Espelund, U., Christiansen, J. S., Jorgensen, J. O., et al. (2014). Serum levels of bioactive IGF-I and physiological markers of ageing in healthy adults. Eur. J. Endocrinol. 170, 229–236. doi: 10.1530/EJE-13-0661
Walenkamp, M. J., Karperien, M., Pereira, A. M., Hilhorst-Hofstee, Y., van Doorn, J., Chen, J. W., et al. (2005). Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. *J. Clin. Endocrinol. Metab.* 90, 2855–2864. doi: 10.1210/jc.2004-1254

Wan, G., and Corfas, G. (2015). No longer falling on deaf ears: mechanisms of degeneration and regeneration of cochlear ribbon synapses. *Hear. Res.* 329, 1–10. doi: 10.1016/j.heares.2015.04.008

Watanabe, T., Miyazaki, A., Katagiri, T., Yamamoto, H., Idei, T., and Iguchi, T. (2005). Relationship between serum insulin-like growth factor-I levels and Alzheimer’s disease and vascular dementia. *J. Am. Geriatr. Soc.* 53, 1748–1753. doi: 10.1111/j.1532-5415.2005.53524.x

Welch, D., and Dawes, P. J. (2007). Childhood hearing is associated with growth rates in infancy and adolescence. *Pediatr. Res.* 62, 495–498. doi: 10.1203/PDR.0b013e3181425869

Wit, J. M., Oostdijk, W., Losekoot, M., van Duyvenvoorde, H. A., Ruivenkamp, C. A., and Kant, S. G. (2016). Mechanisms in endocrinology: novel genetic causes of short stature. *Eur. J. Endocrinol.* 174, R145–R173. doi: 10.1530/EJE-15-0937

Wong, A. C., and Ryan, A. F. (2015). Mechanisms of sensorineural cell damage, death and survival in the cochlea. *Front. Aging Neurosci.* 7:58. doi: 10.3389/fnagi.2015.00058

Woods, K. A., Camacho-Hübner, C., Savage, M. O., and Clark, A. J. (1996). Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. *N. Engl. J. Med.* 335, 1363–1367. doi: 10.1056/NEJM199610313351805

Wrigley, S., Arafa, D., and Tropea, D. (2017). Insulin-like growth factor 1 at the crossroads of brain development and aging. *Front. Cell. Neurosci.* 11:14. doi: 10.3389/fncel.2017.00014

Yamahara, K., Nakagawa, T., Ito, J., Kinoshita, K., Omori, K., and Yamamoto, N. (2017). Netrin 1 mediates protective effects exerted by insulin-like growth factor 1 on cochlear hair cells. *Neuropharmacology* 119, 26–39. doi: 10.1016/j.neuropharm.2017.03.032

Yamahara, K., Yamamoto, N., Nakagawa, T., and Ito, J. (2015). Insulin-like growth factor 1: a novel treatment for the protection or regeneration of cochlear hair cells. *Hear. Res.* 330, 2–9. doi: 10.1016/j.heares.2015.04.009

Yang, Z., Zhang, H., Duan, C. C., Geng, S., Wang, K., Yu, H. F., et al. (2017). IGF1 regulates RUNX1 expression via IRS1/2: implications for antler chondrocyte differentiation. *Cell Cycle* 16, 522–532. doi: 10.1080/15384101.2016.1274471

Yoshida, S., Sugahara, K., Hashimoto, M., Hirose, Y., Shimogori, H., and Yamashita, H. (2015). The minimum peptides of IGF-1 and substance P protect vestibular hair cells against neomycin ototoxicity. *Acta Otolaryngol.* 135, 411–415. doi: 10.3109/00016489.2014.979438

Zou, S., Kamei, H., Modi, Z., and Duan, C. (2009). Zebrafish IGF genes: gene duplication, conservation and divergence, and novel roles in midline and notochord development. *PLoS ONE* 4:e7026. doi: 10.1371/journal.pone.0007026

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2017 Rodríguez-de la Rosa, Lassaletta, Calvino, Murillo-Cuesta and Varela-Nieto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*